- -
- 100%
- +
86
Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-63.
87
Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185:231-2.
88
Bryant JM,Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-60.
89
Plant BJ,GossCH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Resp Med 2013; 1: 164-74.
90
Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-42.
91
Simmonds NJ, Cullinan R Hodson ME. Growing old with cystic fibrosis – the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103: 629-35.
92
Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677-83.
93
Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2013; 7: CD004730.
94
Morales MM, Falkenstein D, Lopes AG. The cystic fibrosis transmembrane regulator (CFTR) in the kidney. An Acad Bras Cienc 2000; 72: 399–406.
95
Jouret F, Devuyst O. CFTRand defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch 2009; 457: 1227-36.
96
Chamnan P, Shine BS, Haworth CS, et al. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33: 311-16.
97
Koch C, Rainisio M, Madessani U, et al. Presence of cystic fibrosis-related diabetes mellitus istightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001: 32: 343-50.
98
Rosenecker J, Hofler R, Steinkamp G, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res 2001: 6: 345-50.
99
Marshall ВС, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005:146: 681-7.
100
Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007:30: 1056-61.
101
Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63.
102
Rowland M, Gallagher CG, O'Laoide R, et al. Outcome in cystic fibrosis liver disease. Am J Gastroenterol 2011;106:104-9.
103
Chryssostalis A, Hubert D, Coste J, et al. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011; 55: 1377-82.
104
Nash EF, Volling C, Gutierrez CA, et al. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis. Clin Transplant 2012; 26: 34–41.
105
AndrieuxA, HarambatJ, BuiS, et al. Renal impairment in children with cystic fibrosis. J Cyst Fibros 2010;9:263-8.
106
O'Connell OJ, Harrison MJ, Murphy DM, et al. Peri-lung transplant renal issues in patients with cystic fibrosis. Chest 2013; 143: 271.
107
Quon BS, Mayer-Hamblett N, Aitken ML, et al. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Ca re Med 2011; 184:1147-52.
108
Paccou J, Zeboulon N, Combescure C, et al. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int 2010; 86: 1–7.
109
Quon BS, Aitken ML. Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev 2012; 13:206-14.
110
Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer 2006; 6: 63–74.
111
Maisonneuve R Marshall ВС, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122-9.
112
Smith DJ, Anderson GJ, Lamont IL, et al. Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. J Cyst Fibros 2013; 12: 303-4.
113
Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332: 494-9.
114
Maisonneuve P, FitzSimmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95: 381-7
115
Johannesson M, Askling J, Montgomery SM, et al. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer 2009; 125: 2953-6.
116
Ploessl C, Pettit RS, Donaldson J. Prevalence of depression and antidepressant therapy use in a pediatric cystic fibrosis population. Ann Pharmacother 2014; 48: 488-93.
117
Riekert KA, Bartlett SJ, Boyle MP, et al. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007; 132: 231-7.
118
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-7.
119
Ploessl C, Pettit RS, Donaldson J. Prevalence of depression and antidepressant therapy use in a pediatric cystic fibrosis population. Ann Pharmacother 2014; 48: 488-93.
120
Riekert KA, Bartlett SJ, Boyle MP, et al. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007; 132: 231-7.
121
LiouTG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 1053-9.
122
Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-5.
123
Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-91.
124
George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007 BMJ 2011; 342: d1008
125
Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/ multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-42.
126
Simmonds NJ, Cullinan R Hodson ME. Growing old with cystic fibrosis – the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103: 629-35.
127
AndrieuxA, HarambatJ, BuiS, et al. Renal impairment in children with cystic fibrosis. J Cyst Fibros 2010;9:263-8.
128
Catherinot E, Roux A-L, Vibet M-A, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013; 12: 74–80.
129
Plant BJ,GossCH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Resp Med 2013; 1: 164-74.
130
Cystic Fibrosis Foundation. Patient registry annual data report 2011. Bethesda: Cystic Fibrosis Foundation; 2011. http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf
131
Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med 2007; 13: 537^10.
132
Schechter MS, Quittner AL, Konstan MW, et al. Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. Ann Am Thorac Soc2013; 10:213-19.
133
GyiKM, HodsonME,YacoubMY. Pregnancy in cystic fibrosis lung transplant recipients: case series and review. J Cyst Fibros 2006; 5: 171-5.
134
Bullough B. Poverty, ethnic identity and preventive health care. J Health Soc Behav 1972: 347-59.
135
Duncan GJ, Brooks-Gunn J. Family poverty, welfare reform, and child development. Child Dev 2000; 71: 188-96.
136
Wagstaff A. Poverty and health sector inequalities. Bull World Health Organ 2002; 80: 97-105.
137
Cystic Fibrosis Foundation. Patient registry annual data report 2011. Bethesda: Cystic Fibrosis Foundation; 2011. http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf
138
Targett K, Bourke S, Nash E, et al. Employment in adults with cystic fibrosis. Occup Med 2014; 64: 87–94.
139
Boyle MP, Sabadosa KA, Quinton HB, et al. Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project. BMJ Qual Saf 2014; 23 (Suppl 1): i15-i22.
140
Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research. BMJ Qual Saf 2014; 23: 508-18.
141
Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: best practice guidelines. J Cyst Fibros 2014; 13: S23-S42.
142
Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society Standards of Care: framework for the cystic fibrosis centre. J Cyst Fibros 2014; 13: S3-S22.
143
Stern M, Bertrand DP, Bignamini E, et al. European Cystic Fibrosis Society Standards of Care: quality management in cystic fibrosis. J Cyst Fibros 2014; 13: S43-S59.
144
Klimes Ji, Dolezal T, Kubackova K, et al. Health-economic aspects of cystic fibrosis screening and therapy. In: Mall MA, Elborn JS, eds. Cystic fibrosis. Eur Resp Monogr 2014; 64: 304–319.
145
Buzzetti R, Salvatore D, Baldo E, et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J Cyst Fibros 2009; 8: 229-37.
146
Flume PA, Strange C, Ye X, etal. Pneumothorax in cystic fibrosis. Chest 2005; 128:720-8.
147
Flume PA, Strange C, Ye X, etal. Pneumothorax in cystic fibrosis. Chest 2005; 128:720-8.
148
Flume PA, Strange C, Ye X, etal. Pneumothorax in cystic fibrosis. Chest 2005; 128:720-8.
149
Phillips GD, Trotman-Dickenson B, Hodson ME, et al. Role of CT in the management of pneumothorax in patients with complex cystic lung disease. Chest 1997; 112:275-8.
150
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
151
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
152
Amin R, Noone PG, Ratjen F. Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. Cochrane Database Syst Rev 2012; 12: CD007481.
153
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
154
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
155
Curtis HJ, Bourke SJ, Dark JH, et al. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24: 865-9.
156
Rolla M, Anile M,Venuta F, etal. Lung transplantation for cystic fibrosis after thoracic surgical procedures. Transplant Proc 2011; 43: 1162-3.
157
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
158
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
159
Flume PA, Strange C, Ye X, etal. Pneumothorax in cystic fibrosis. Chest 2005; 128:720-8.
160
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
161
Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013; 17: 991-4.
162
Moua J, Nussbaum E, Liao E, et al. Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach. Ther Adv Respir Dis 2013;7:217-23.
163
Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128: 729-38.
164
Barben JU, Ditchfield M, Carlin JB, et al. Major haemoptysis in children with cystic fibrosis: a 20-year retrospective study. J Cyst Fibros 2003; 2: 105-11.
165
Giron Moreno RM, Caballero R Friera A. Multidetector computed tomography angiography for pre-embolization assessment in cystic fibrosis patients with massive haemoptysis. Respir Med 2014; 108:816-7.
166
Cornalba GP, Vella A, Barbosa F, et al. [Bronchial and nonbronchial systemic artery embolization in managing haemoptysis: 31 years of experience], Radiol Med 2013; 118: 1171-83.
167
Pestana Knight EM, Novelli PM, Joshi SM. Cerebral and systemic infarcts after bronchial artery embolization. Pediatr Neurol 2011;45:324-7.
168
Daliri A, Probst NH,Jobst В et al. Bronchial artery embolization in patients with hemoptysis including follow-up. Acta Radiol 2011; 52: 143-7.
169
Lau EM,Yozghatlian V, Kosky C, et al. Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis. Chest 2009; 136:277-81.
170
Rolla M, D'Andrilli A, Rendina EA, et al. Cystic fibrosis and the thoracic surgeon. Eur J Cardiothorac Surg 2011; 39: 716-25.
171
Jones A, Bilton D, Evans TW, et al. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology 2013; 18: 630-6.
172
Middleton PG, Chen SC, Meyer W. Fungal infections and treatment in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 670-5.
173
Agarwal R, Chakrabarti A, Shah A, et al. ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73.
174
Geller DE, Kaplowitz H, Light MJ, et al. Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest 1999; 116: 639-46.
175
Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000; 16: 464-71.
176
Agarwal R, Chakrabarti A, Shah A, et al. ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73.
177
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
178
Agarwal R, Khan A, GargM,etal. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol 2012; 4: 141-50.
179
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
180
Hemmann S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.
181
Nikolaizik WH,Weichel M, Blaser K, et al. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165: 916-21.
182
Hemmann S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.
183
Fricker-Hidalgo H, Coltey B, Llerena C, et al. Recombinant allergens combined with biological markers in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Clin Vaccine Immunol 2010; 17: 1330-6.
184
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
185
Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.
186
Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.
187
Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal antibody. J R Soc Med 2009; 102(Suppl 1): 49–53.
188
Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal antibody. J R Soc Med 2009; 102(Suppl 1): 49–53.
189
Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 6: CD002204.
190
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
191
Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63: 438-50.
192
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
193
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
194
Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49: 503-7.
195
Jat KR, Walia DK, Khairwa A. Anti-lgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2013; 9:CD010288.
196
Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New Engl J Med 1996; 335: 179-88.
197
Hayes D Jr, Higgins RS, Kirkby S, et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. J Cyst Fibros 2014; 13: 416-23.
198
Toneili AR. Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 652-61.
199
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
200
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
201
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
202
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.
203
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.
204
Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-7.
205
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.